$INVA News

HC Wainwright & Co. Reiterates Buy on Innoviva, Maintains $46 Price Target

BTIG Reiterates Buy on Innoviva, Maintains $42 Price Target

INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals

BTIG Maintains Buy on Innoviva, Raises Price Target to $42

Innoviva Q1 EPS $2.22 Beats $0.36 Estimate, Sales $97.994M Miss $101.555M Estimate

3 Bargain-Cheap Small Caps Worth a Second Look

Beacon Biosignals Upsizes Series B Financing to Over $97 Million

Innoviva Inc (NASDAQ:INVA) Screened as a Top Value Stock with Strong Fundamentals

Analysts See This Pharma Stock Surging 60%; Eyes Fresh Entry

Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains

Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report

INNOVIVA INC (NASDAQ:INVA) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template

Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s Why

Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price Run

Innoviva, Inc. (INVA): A Bull Case Theory

Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference

Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

BTIG Reiterates Buy on Innoviva, Maintains $35 Price Target

Innoviva: Q4 Earnings Snapshot